Originally published Tuesday, August 5, 2008 at 12:00 AM
ImClone takes dim view of offer
ImClone Systems' board of directors said Monday cancer-drug partner Bristol-Myers Squibb's $4.5 billion buyout offer "substantially undervalues"...
The Associated Press
NEW YORK — ImClone Systems' board of directors said Monday cancer-drug partner Bristol-Myers Squibb's $4.5 billion buyout offer "substantially undervalues" the company, with Chairman Carl Icahn personally against the deal.
Despite calling the bid too low, ImClone stopped short of rejecting it and said its board formed a committee to weigh the offer. The board said it is considering splitting the company into two units to focus on cancer drug Erbitux and its developing pipeline separately.
The companies are partners on the colon- and head-and-neck-cancer treatment Erbitux. They are also currently developing the drug as a lung-cancer therapy.
"As we stated last week, we believe we've made a fair offer and we look forward to a response from ImClone's board on that offer," Bristol-Myers spokeswoman Tracy Furey said.
Analysts and investors both expected a cold response from ImClone as many view Erbitux and the company's pipeline as more valuable than the buyout offer implies. Shares have reflected this, consistently trading above the offer price.
Bristol-Myers is offering $60 per share, a 30 percent premium to ImClone's stock price before the offer, made on Thursday.
"While the news regarding a potential ImClone restructuring was unexpected, ImClone's response to the initial Bristol-Myers offer was not," Thomas Weisel Partners analyst Stephen Willey said in a statement.
Icahn, who is also one of the company's largest stockholders, is personally against the deal, according to a statement from ImClone. He is also "disturbed" that one of his directors who is also a Bristol-Myers designee might have been privy to confidential discussions by ImClone over the possibility of splitting the company.
John Celentano, Bristol-Myers' senior vice president of strategy and productivity transformation, is the board designee to ImClone.
"Accordingly, the board is reviewing whether Bristol-Myers had access to confidential information concerning ImClone and its pipeline," the company said.
Bristol-Myers owns about 16 percent of ImClone's stock based on the number of shares outstanding as of June 30. The company said it was not privy to any confidential information and continues to take measures to ensure such information is not exchanged by either company.
Icahn also said the company's developing cancer drug IMC-11F8 could be a potential competitor to Erbitux, and Bristol-Myers might not have rights to that drug under its current deal with ImClone.
![]()
Icahn, a billionaire activist investor, won control of ImClone in 2006 after a proxy battle that led to the departure of CEO Joseph Fischer and four board members. He owns about 13 percent of the company.
At the time of the takeover, Icahn said he planned to investigate why ImClone's relationship with Bristol-Myers had "seriously deteriorated" after a public feud over Erbitux.
In a conference call Thursday, Bristol-Myers Chairman and Chief Executive James Cornelius commended Icahn for his leadership at ImClone and said the relationship between both companies has "blossomed" since the management change.
Icahn, meanwhile, is facing issues on other fronts. WCI Communities, of which he is also chairman, filed for Chapter 11 bankruptcy Monday, as the builder of retirement homes and "lifestyle communities" gets battered by a weak housing market.
In June, Icahn lost his ImClone-style takeover bid for fellow biotechnology company Biogen Idec. He attempted to put three of his nominees on the board of directors in the hopes that it would eventually trigger a sale, but shareholders voted instead for the current board's nominees.
ImClone shares fell 31 cents to $65.03 Monday, while shares of Bristol-Myers rose 28 cents to $21.39.
Copyright © 2008 The Seattle Times Company
Nintendo re-enlists Mario, savior of video-game industry
Verizon-Frontier deal stirs concern among consumers
Brier Dudley: 'Guitar Hero' founder excited about future
Gaps for consumers in Democrat health care bills
Hutch gets $10M from Bezos family for immunotherapy research

Real Salt Lake wins MLS Cup
Real Salt Lake defeated the Los Angeles Galaxy with penalty kicks after 120 minutes of play at Qwest Field in Seattle.
nwautos
Local riders say they've seen a surge in scooter interest in recent years, mostly from people wanting another commuting option. Seattle now ranks as o...
Post a comment
nwjobs
Post a comment
Michelle Goodman blogs about work/life balance.
Do you suffer from "sitting disease"?
Post a comment
- 'The Road' takes Viggo Mortensen to Mount St. Helens and Astoria, Ore.
- Tugboat sinks at Seattle waterfront pier
- Illegal workers quietly let go
- Child-support error costs nearly $21,000
- Vikings easily beat the Seahawks
- Craigslist adoption ad: A plea by young mother-to-be? A scam?
- Chase shrugs off loss of CD investors
- Woman stabbed by stranger in North Seattle
- Snow piles up on Cascade slopes
- Denny Triangle gains skyline, but tenants slow to come
- Illegal workers quietly let go
303 - Climate change speeds up since 1997 Kyoto accord
181 - Vikings easily beat the Seahawks
169 - Metro won't cut bus service after all
126 - Historic health care bill clears Senate hurdle
93 - Tattoos at Mill Creek Church pierce skin, soul
73 - Jerry Brewer: Seahawks can't lean on the Hutch Crutch now
67 - UW, WSU once again meet to see who's worse
62 - New Husky recruit: Enes Kanter
60 - Ranking the Pac
53
- Sprouts, raw fish on attorney's 'do not eat' list
- Tattoos at Mill Creek church pierce skin, soul
- Illegal workers quietly let go
- Food-safety lawyer's wish: Put me out of business
- Rediscovering Moab, 'the most beautiful place on Earth'
- It's possible to recover a life lost to hoarding
- Architects, chefs find 'kid' within to build Gingerbread Village
- Child-support error costs nearly $21,000
- 'The Road' takes Viggo Mortensen to Mount St. Helens and Astoria, Ore.
- Taste | The Great Pie Bake-off pits friends and fruit








